Investors Overview


MiMedx® is an integrated developer, processor and marketer of patent protected and proprietary regenerative biomaterial products and bioimplants processed from human amniotic membrane and other birth tissues and human skin and bone. “Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself. The MiMedx allograft product families include our: dHACM family with AmnioFix®, EpiFix® and EpiBurn® brands; Amniotic Fluid family with OrthoFlo brand; Umbilical family with EpiCord™ and AmnioCord™ brands; Placental Collagen family with CollaFix™ and AmnioFill™ brands; Bone family with Physio® brand; and Skin family with AlloBurn™ brand. AmnioFix, EpiFix, and EpiBurn are our tissue technologies processed from human amniotic membrane; OrthoFlo is an amniotic fluid derived allograft; EpiCord™ and AmnioCord™ are derived from the umbilical cord; Physio is a unique bone grafting material comprised of 100% bone tissue with no added carrier; AlloBurn is a skin product derived from human skin designed for the treatment of burns; and CollaFix, our next brand we plan to commercialize, is our collagen fiber technology, developed with our patented cross-linking polymers, designed to mimic the natural composition, structure and mechanical properties of musculoskeletal tissues in order to augment their repair. We process the human amniotic membrane utilizing our proprietary PURION® Process, to produce a safe and effective implant. MiMedx proprietary processing methodology employs aseptic processing techniques in addition to terminal sterilization. MiMedx is the leading supplier of amniotic tissue, having supplied over 700,000 allografts to date for application in the Wound Care, Burn, Surgical, Orthopedic, Spine, Sports Medicine, Ophthalmic and Dental sectors of healthcare.

ExchangeNASDAQ CM (US Dollar)
Change Stock is Up 0.43 (2.89%)

06/28/17  4:00 p.m. ET

Minimum 20 minute delay

Stock chart for: MDXG.O.  Currently trading at $15.30 with a 52 week high of $16.20 and a 52 week low of $6.94.
Data Provided by Thomson Reuters


View All
Scientific And Clinical Review Confirms Potential Of MiMedx dHACM Allografts For Regenerative Applications In OrthopedicsdHACM Allografts Retain Growth Factors And Bioactive Proteins Shown To Regulate Activity Of Cell Types, Including Stem Cells, That Are Critical To Orthopedic Repair Of Injured And Diseased

Read More

MiMedx Amniofix® data showing colorectal anastomotic leak rate reduction presented at ASCRS MeetingMARIETTA, Ga., June 13, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative and therapeutic biologics utiliz

Read More

MiMedx to Present at the Jefferies 2017 Global Healthcare ConferenceMARIETTA, Ga., June 1, 2017 /PRNewswire/ -- MiMedx Group, Inc. (NASDAQ: MDXG), the leading biopharmaceutical company developing and marketing regenerative biologics utilizing human placent

Read More


Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever MIMEDX GROUP INC posts new information to the site. Just enter your e-mail address and click Submit.